Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of VX-661 alone and VX-661 plus ivacaftor in cystic fibrosis with F508del CFTR mutation
2011-003821-93Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of tezacaftor and ivacaftor in cystic fibrosis (CF) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Safety. Started Dec 2011; status: completed.
02
Drugs
tezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2011-003821-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003821-93.